Results 161 to 170 of about 128,004 (314)

Cardiotoxicity of BRAF/MEK inhibitors

British Journal of Pharmacology, EarlyView.
Abstract Rapidly accelerated fibrosarcoma type B/B‐Raf proto‐oncogene, serine/threonine kinase (BRAF) and mitogen‐activated protein kinase (MEK) inhibitors have transformed outcomes in cancer therapy, particularly in melanoma. However, cardiovascular toxicities are increasingly recognized in real‐world clinical practice.
Katharina Seuthe, Valerie Lohner, Kevin Terre, Thomas Riffelmacher, Roman Pfister   +4 more
wiley   +1 more source

Gβγ subunit activation of KV7 and BKCa channels underlies calcitonin gene‐related peptide vasorelaxation in myogenic rat coronary resistance arteries

British Journal of Pharmacology, EarlyView.
Abstract Background and Purpose CGRP is a potent, clinically relevant coronary vasodilator known to play a role in cardioprotection. Here, we investigated the precise intracellular signalling pathways leading to vasodilation in small coronary arteries.
Lucy A. Donovan, JinHeng Lin, Milind Khashu, Christopher J. Garland, Kim A. Dora   +4 more
wiley   +1 more source

Cardiovascular toxicity from immune checkpoint inhibitor therapy: an inflammatory continuum

British Journal of Pharmacology, EarlyView.
Immune checkpoint inhibitor (ICI) therapy has markedly improved outcomes in advanced malignancies but has also revealed a distinct spectrum of cardiovascular immune‐related adverse events. Myocarditis represents the most severe manifestation, while non‐inflammatory left ventricular dysfunction and vascular inflammation have emerged as additional ...
Fabrice Reyes, Florian Buehning, Tobias Lerchner, Julia Vogel, Raluca I. Mincu, Matthias Totzeck, Tienush Rassaf, Lars Michel   +7 more
wiley   +1 more source

Comprehensive Endotyping of Patients With Angina and Nonobstructive Coronary Arteries: A Report From the J‐CMD

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background Angina with nonobstructive coronary arteries (ANOCA) is frequently driven by coronary vasospasm and coronary microvascular dysfunction (CMD).
Masahiro Hada, Tsunekazu Kakuta, Hiroki Ueno, Yoshihisa Kanaji, Eisuke Usui, Tatsuhiro Nagamine, Kodai Sayama, Takumi Watanabe, Takahiro Watanabe, Hikaru Shimosato, Riko Murakami, Takashi Mineo, Shunta Hiroi, Kaisei Hosokawa, Taishi Yonetsu, Tetsuo Sasano, Morihiko Takeda, Kenichi Tsujita, Hiroaki Shimokawa   +18 more
doaj   +1 more source

AMPK‐mediated prevention of vascular dysfunction with metformin: Experimental and population‐based evidence

British Journal of Pharmacology, EarlyView.
Angiotensin II induces vascular inflammation, senescence, extracellular matrix (ECM) degradation and endothelial dysfunction, thus impairing SK+/IK+ channel function and reducing endothelial‐dependent hyperpolarisation (EDH). Metformin activates AMPK, increasing SK+/IK+ channel function and restoring vasorelaxation.
Soroush Mohammadi Jouabadi, Annika A. Jüttner, Annique Claringbould, Rene de Vries, Ingrid M. Garrelds, Usha Musterd‐Bhaggoe, Bruno H. Stricker, Maryam Kavousi, A. H. Jan Danser, Fariba Ahmadizar, Anton J. M. Roks   +10 more
wiley   +1 more source

Immune checkpoint inhibitor‐induced arrhythmias: Mechanistic insights from clinical and preclinical studies

British Journal of Pharmacology, EarlyView.
Immune checkpoint inhibitors (ICIs) have transformed cancer therapy, but their efficacy continues to be limited by immune‐related adverse events. Among these, ICI‐induced cardiac arrhythmias are increasingly recognised as a major adverse reaction, encompassing a broad spectrum of clinical phenotypes, including conduction blocks, atrial fibrillation and
Anand R. Ramalingam, Zoltán Márton Köhler, Péter Ferdinandy, Zoltán V. Varga   +3 more
wiley   +1 more source

Evaluation of the Safety, Efficacy and Pharmacokinetics of BGM0504 in Chinese Adults With Type 2 Diabetes: A Multicentre, Randomised, Controlled and Double‐Blind Phase II Trial

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aim This study aimed to evaluate its safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy in Chinese adults with T2DM and to preliminarily compare its efficacy and safety with semaglutide through multiple subcutaneous injections. Materials and Methods In this multicentre, randomised, placebo‐controlled and semaglutide‐positive‐
Ping Jin, Linong Ji, Yangqing Huang, Haifeng Ding, Daosheng Xie, Xiaohui Jiang, Xuemei Yuan, Zhao Cao, Haibin Zhang, Jiandong Yuan   +9 more
wiley   +1 more source

Prediabetes, Malignant Ventricular Hypertrophy and Stroke: The SPRINT Trial

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Prediabetes and left ventricular hypertrophy (LVH) are common risk factors in adults with hypertension. Whether their coexistence, particularly in the presence of subclinical myocardial injury or stress (malignant LVH), confers a heightened stroke risk is unknown.
Arnaud D. Kaze, Stephen P. Juraschek, Jordana B. Cohen, Siddharth Singh, Chiadi E. Ndumele, Christie M. Ballantyne, Jarrett D. Berry, Justin B. Echouffo‐Tcheugui   +7 more
wiley   +1 more source

Coronary microvascular dysfunction in childhood: An emerging pathological entity and its clinical implications

American Heart Journal Plus
Coronary microvascular dysfunction (CMD) encompasses a spectrum of structural and functional alterations in coronary microvasculature resulting in impaired coronary blood flow and consequent myocardial ischemia without obstruction in epicardial coronary ...
Takeshi Tsuda, Gina Patel
doaj   +1 more source

Coronary microvascular dysfunction beyond the spectrum of chronic coronary syndromes

The prevalence of coronary microvascular dysfunction (CMD) beyond the spectrum of chronic coronary syndromes (CCS) is non-negligible, pertaining to pathophysiological and therapeutical implications. Thanks to the availability of accurate and safe non-
Antonio De Vita, MD8, Roberto Scarsini, MD PhD6, MD PhD3, MD9, Emanuele Gallinoro, MD PhD7, Pasquale Paolisso, MD4 5, Sara Amicone, MD PhD12, Pasquale Perrone Filardi, Marta Belmonte, MD10, Alberto Foà, Luca Bergamaschi, Saverio Muscoli, MD2 on behalf of the Coronary Physiopathology and Microcirculation Working Group of the Italian Society of Cardiology (SIC)., MD PhD11, MD, PhD16 and Carmine Pizzi, MD14 15, MD PhD1, Gaetano Antonio Lanza, MD PhD2, Alberto Polimeni, Ciro Indolfi, 13, Flavio Ribichini MD, Francesco Angeli, Doralisa Morrone, Vincenzo Sucato, PhD6, Saverio Tremamunno, Matteo Armillotta, Alaide Chieffo, MD2, Angelo Villano, MD1, Emanuele Barbato   +40 more
core   +1 more source